Concerns about a number of serious side effects have been linked to the new diabetes drug Invokana (canagliflozin), including reports of users who have experienced kidney failure, heat attacks, strokes and dangerously high blood acid levels, known as ketoacidosis.

Invokana is an oral medication for treatment of type 2 diabetes, which is part of a new class of drugs that work by inhibiting the normal function of the kidney to lower blood sugar in patients.  Other members of this same class, which have been linked to similar side effects, including Invokamet, Farxiga, Xigduo XR, Jardiance and Glyxambi.

Although these other new drugs were introduced as a safe and effective diabetes treatments, adverse event reports suggest that the drug makers may have failed to adequately research their medication or warn about the potential side effects of Invokana. As a result, the potential for product liability lawsuits are being reviewed by the lawyers at Saiontz & Kirk, P.A. for individuals who have experienced:

  • Diabetic Ketoacidosis (DKA)
  • Hospitalization for Nausea, Vomiting, Breathing Problems or Other Symptoms of Ketoacidosis
  • Renal or Kidney Failure
  • Kidney Transplant Surgery
  • Heart Attack
  • Stroke
  • Wrongful Death

The Invokana injury lawyers at Saiontz & Kirk, P.A. are pursuing potential failure to warn claims for individuals throughout the United States who may have suffered problems caused by the diabetes drug. Request a free consultation and claim evaluation.

Invokana Ketoacidosis Risk

Only two years after the medication was introduced, the FDA issued warnings about the potential risk of Invokana ketoacidosis side effects, following reports that suggest the medication may cause high levels of acid to accumulate in the blood.

Invokana Injury Lawsuit

Invokana Injury Lawsuits

The lawyers at Saiontz & Kirk are investigating potential cases for individuals throughout the United States who have experienced side effects of Invokana.

As a result of the drug maker’s failure to warn, diabetes patients have been left with serious and potentially life-threatening health problems.


Diabetic ketoacidosis is a serious medical condition that often results in the need for hospitalization and could lead to death. While it is usually rare among patients with type 2 diabetes, which Invokana is designed to treat, a number of FDA adverse event reports have been received involving users of Invokana diagnosed with ketoacidosis.

The FDA first issued a drug safety communication to indicate that it was investigating the link between Invokana and ketoacidosis in May 2015.

On December 4, 2015, the agency indicated that new ketoacidosis warnings were being required for the entire class of diabetes drugs, advising patients to stop using the drug immediately and seek medical assistance if they began experiencing signs of ketoacidosis.

Between March 2013 and May 2015, the FDA identified at least 73 cases of acidosis diagnosed as diabetic ketoacidosis, ketoacidosis or ketosis among patients treated with Invokana or other drugs in the same class.

Each of the ketoacidosis cases on Invokana or another SGLT2 inhibitor diabetes drug resulted in the need for emergency room treatment or hospitalization.

The FDA urged patients to seek immediate medical attention if they experience symptoms of ketoacidosis on Invokana, including:

  • Breathing Difficulty or Respiratory Problems
  • Nausea, Vomiting or Abdominal Pain
  • Confusion, Fatigue or Sleepiness

As federal drug regulators continue to investigate the Invokana ketoacidosis risk and determine whether Johnson & Johnson should be required to take additional steps to protect patients, it is important for individuals who were hospitalized due to complications from Invokana to take steps to protect their legal rights by contacting Saiontz & Kirk, P.A. for a free consultation.

Invokana Kidney Failure Problems

During the first two years the new diabetes drug was on the market in the United States, there have also been an alarming number of reports involving problems that may be caused by potential Invokana kidney side effects.

According to a report (PDF) released by the Institute for Safe Medication Practices (ISMP) in May 2015, Invokana problems were reported involving at least 457 patients during the first year the drug was on the market, including at least five different categories of kidney toxicity, including:

  • Kidney Failure or Renal Impairment
  • Dehydration and Fluid Imbalances
  • Kidney Stones
  • Urinary Tract Infections
  • Abdnormal Weight Loss

In December 2015, the FDA required the makers of SGLT2 inhibitors to add new warnings about the potential risk of urinary tract infections, as this could be an indication of a more dangerous blood or kidney infection that could lead to kidney failure and even death.

Since Invokana works by blocking kidney function, causing substantial amounts of sugar to be excreted through urine, many experts have suggested that the link between Invokana and renal failure should have been known or suspected before it was ever introduced. However, it appears that inadequate warnings were provided for consumers or the medical community about the risk of Invokana kidney side effects.

Invokana Failure to Warn Lawsuits

Since putting Invokana on the market, Johnson & Johnson has aggressively marketed the new diabetes treatment, attempting to capitalize on the “first-to-market” status among this new class of drugs. In addition, the drug was introduced amid mounting safety concerns over several other popular diabetes drugs, including Actos, Byetta, Januvia, Janumet, Onglyza, Victoza and Avandia.

While failing to adequately warn consumers and the public about the potential Invokana side effects, Johnson & Johnson was able to quickly grow their new diabetes treatment into blockbuster medication, with more than $278 million in sales during the first quarter of 2015 alone.

Some experts have suggested that the potential Invokana risks may outweigh the minimal benefits provided in treating type 2 diabetes. As a result, the lawyers at Saiontz & Kirk, P.A. believe the FDA should strongly consider issuing an Invokana recall. At a minimum, the drug makers should have provided stronger warnings earlier, so that consumers and doctors could make an informed decision about whether to use Invokana.

Potential Invokana failure to warn lawsuits are being reviewed by our law firm for individuals throughout the United States. All cases are handled on a contingency fee basis, which means that there are no out-of-pocket expenses to hire Saiontz & Kirk, P.A. Attorney fees and expenses are only received by our lawyers if we are successful obtaining compensation for side effects of Invokana.